Abstract

To evaluate the prevalence of HPV DNA and cervical cytological abnormalities, to compare cervical cytology results and HPV DNA and to define HPV types distribution in a large series of Turkish women who have undergone HPV analysis in hospitals that are members of the Turkish Gynecological Oncology Group. Between 2006 and 2010, a total of 6388 patients' data was retrospectively evaluated at 12 healthcare centers in Turkey. Demographic characteristics, cervical cytology results, HPV status and types were compared. The mean age of the patients was 38.9±10.2. Overall, 25% of the women were found to be HPV positive. Presence of HPV-DNA among patients with abnormal and normal cytology was 52% and 27%, respectively. There was significant difference with respect to decades of life and HPV positivity (p < 0.05). HPV was positive in (within the HPV (+) patients) 37%, 9%, 27%, 20%, 22%, and 41% of the ASCUS, ASC-H, LSIL HSIL, glandular cell abnormalities, and SCC cases respectively The most common HPV types in our study were as follows; HPV 16 (32%), HPV 6 (17%), HPV 11 (9%), HPV 18 (8%), HPV 31 (6%), HPV 51 (5%), HPV 33 (3%). In this hospital based retrospective analysis, HPV genotypes in Turkish women with normal and abnormal cytology are similar to those reported from western countries. Further population based prospective multicenter studies are necessary to determine non-hospital based HPV prevalence in Turkish women.

Highlights

  • Worldwide, cervical cancer is the second most common and the fifth deadliest cancer in women [1, 2]

  • The vaccine is effective against type 6 and 11 which cause more than 90% of anogenital warts and recurrent respiratory papillomatosis

  • A total of 6388 women who applied for regular gynecological examination were analyzed for HPV at twelve Health Centers in Turkey

Read more

Summary

Introduction

Cervical cancer is the second most common and the fifth deadliest cancer in women [1, 2]. It affects about 16 per 100,000 women per year and kills about 9 per 100,000 per year [3]. In 2008, it was estimated that there were 473,000 cases of cervical cancer, and 253,500 deaths per year majority of which is preventable with the HPV vaccine [4]. Accurate information about HPV prevalence is needed to make vaccination recommendations. The widespread use of cervical screening programs has dramatically reduced the incidence of invasive cervical cancer [5]

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call